Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

PALISADE BIO, INC.

PALI · Nasdaq · CIK 0001357459 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

8 qualifying P purchase groups
in the current 180-day scoring window

26 Form 4 transaction lines observed in the same window
2 sales · 16 option, withholding, award, gift or other lines

Last qualifying purchase2026-10-02 · Williams Donald Allen · $14.6K

WHY NO ACTIVE SIGNAL?

Purchase activityPresent
Recent buying8 qualifying line group(s)
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Baltera Robert Jr.Director
○●●●●●●
Finley John DavidCEO, CFO
○○▼○○○
Jones Mitchell LawrenceChief Medical Officer
○▼○○
Williams Donald AllenDirector
○○●●
Wei BinxianDirector
○○
Chuang EmilDirector
○○
● Purchase▼ Sale○ Other

Showing the six most active owners; 1 additional owner(s) remain in Form 4 evidence.

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION90%Largest buyer: Baltera Robert Jr. · $250.1K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-07-01–2026-07-09

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-10-02 · Williams Donald Allen.

Recent Form 4 activity

10Purchases
4Sales
18Other Form 4 lines
18SEC filings · 365 days
BUYING8 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER16 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-23.4%
3M
-18.5%
6M
-15.4%
12M
-23.0%

Volatility & liquidity

Volatility
119.2%
Beta
—
Avg daily value
USD 3.9M

Valuation

Market cap
USD 268.4M
P/E
—

Fundamentals

Profit margin
—
ROE
-13.0%
Industry
Biotechnology

Market data

Price data up to: 2026-10-09 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-06 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
31,015,282
Previous report
30,267,286
Avg daily volume
5,116,812
Days to cover
6.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-02Williams Donald AllenPurchase (P)Common Stock10,000USD 1.46USD 14,600SEC filing ↗
2026-10-01Williams Donald AllenPurchase (P)Common Stock10,000USD 1.42USD 14,200SEC filing ↗
2026-07-09Baltera Robert Jr.Purchase (P)Common Stock25,000USD 1.96USD 49,000SEC filing ↗
2026-07-08Baltera Robert Jr.Purchase (P)Common Stock20,000USD 1.99USD 39,800SEC filing ↗
2026-07-07Baltera Robert Jr.Purchase (P)Common Stock30,000USD 2.03USD 60,900SEC filing ↗
2026-07-06Baltera Robert Jr.Purchase (P)Common Stock20,000USD 2.05USD 41,000SEC filing ↗
2026-07-02Baltera Robert Jr.Purchase (P)Common Stock10,000USD 1.98USD 19,800SEC filing ↗
2026-07-01Baltera Robert Jr.Purchase (P)Common Stock20,000USD 1.98USD 39,600SEC filing ↗
2026-01-16Williams Donald AllenPurchase (P)Common Stock5,000USD 1.67USD 8,350SEC filing ↗
2026-01-09Williams Donald AllenPurchase (P)Common Stock5,000USD 1.88USD 9,400SEC filing ↗
2024-05-28Williams Donald AllenPurchase (P)Comon Stock, par value $0.011,000USD 4.86USD 4,860SEC filing ↗
2024-05-24Finley John DavidPurchase (P)Common Stock, par value $0.011,000USD 4.81USD 4,810SEC filing ↗
2024-02-06Finley John DavidPurchase (P)Common Stock, par value $0.0110,000USD 0.47USD 4,700SEC filing ↗
2024-01-31Williams Donald AllenPurchase (P)Common Stock, par value $0.0110,000USD 0.61USD 6,100SEC filing ↗
2024-01-31Finley John DavidPurchase (P)Common Stock, par value $0.0110,000USD 0.56USD 5,600SEC filing ↗

Form 4 evidence

32 transaction lines in the latest 365-day window; 119 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-06Jones Mitchell LawrenceOption exercise / conversion (M)Common Stock2,620,850USD —USD —SEC filing ↗
2026-10-06Jones Mitchell LawrenceTax withholding (F)Common Stock1,031,102USD 1.49USD 1,536,342SEC filing ↗
2026-10-06Finley John DavidOption exercise / conversion (M)Common Stock3,227,384USD —USD —SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-06Jones Mitchell LawrenceOption exercise / conversion (M)Common Stock2,620,850USD —USD —SEC filing ↗
2026-10-06Jones Mitchell LawrenceTax withholding (F)Common Stock1,031,102USD 1.49USD 1,536,342SEC filing ↗
2026-10-06Finley John DavidOption exercise / conversion (M)Common Stock3,227,384USD —USD —SEC filing ↗
2026-10-06Finley John DavidTax withholding (F)Common Stock1,411,982USD 1.49USD 2,103,853SEC filing ↗
2026-10-02Williams Donald AllenPurchase (P)Common Stock10,000USD 1.46USD 14,600SEC filing ↗
2026-10-01Williams Donald AllenPurchase (P)Common Stock10,000USD 1.42USD 14,200SEC filing ↗
2026-08-19Finley John DavidGift (G)Common Stock88,400USD 0.00USD 0SEC filing ↗
2026-07-09Baltera Robert Jr.Purchase (P)Common Stock25,000USD 1.96USD 49,000SEC filing ↗
2026-07-08Baltera Robert Jr.Purchase (P)Common Stock20,000USD 1.99USD 39,800SEC filing ↗
2026-07-07Jones Mitchell LawrenceSale (S)Common Stock51,880USD 2.05USD 106,354SEC filing ↗
2026-07-07Finley John DavidSale (S)Common Stock146,798USD 2.07USD 303,872SEC filing ↗
2026-07-07Finley John DavidOption exercise / conversion (M)Common Stock133USD 0.70USD 93SEC filing ↗
2026-07-07Baltera Robert Jr.Purchase (P)Common Stock30,000USD 2.03USD 60,900SEC filing ↗
2026-07-06Jones Mitchell LawrenceOption exercise / conversion (M)Common Stock131,167USD —USD —SEC filing ↗
2026-07-06Finley John DavidOption exercise / conversion (M)Common Stock335,167USD —USD —SEC filing ↗
2026-07-06Baltera Robert Jr.Purchase (P)Common Stock20,000USD 2.05USD 41,000SEC filing ↗
2026-07-02Baltera Robert Jr.Purchase (P)Common Stock10,000USD 1.98USD 19,800SEC filing ↗
2026-07-01Baltera Robert Jr.Purchase (P)Common Stock20,000USD 1.98USD 39,600SEC filing ↗
2026-06-10Baltera Robert Jr.Award / grant (A)Common Stock336,904USD —USD —SEC filing ↗
2026-06-10Zwick Jordan MichaelAward / grant (A)Common Stock336,904USD —USD —SEC filing ↗
2026-06-10Williams Donald AllenOption exercise / conversion (M)Common Stock60,666USD —USD —SEC filing ↗
2026-06-10Williams Donald AllenAward / grant (A)Common Stock1,498,900USD —USD —SEC filing ↗
2026-06-10Wei BinxianOption exercise / conversion (M)Common Stock20,200USD —USD —SEC filing ↗
2026-06-10Wei BinxianAward / grant (A)Common Stock592,300USD —USD —SEC filing ↗
2026-06-10Chuang EmilOption exercise / conversion (M)Common Stock20,200USD —USD —SEC filing ↗
2026-06-10Chuang EmilAward / grant (A)Common Stock592,300USD —USD —SEC filing ↗
2026-02-12Jones Mitchell LawrenceSale (S)Common Stock1,989USD 1.75USD 3,481SEC filing ↗
2026-02-12Finley John DavidSale (S)Common Stock3,896USD 1.75USD 6,818SEC filing ↗
2026-02-11Jones Mitchell LawrenceOption exercise / conversion (M)Common Stock8,000USD —USD —SEC filing ↗
2026-02-11Finley John DavidOption exercise / conversion (M)Common Stock13,333USD —USD —SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerPALI
CIK0001357459
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history119 transaction lines from 2021-04-27 to 2026-10-06
34 P purchase lines · 5 S sale lines · 80 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.